<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01212263</url>
  </required_header>
  <id_info>
    <org_study_id>MansouraIFC1</org_study_id>
    <nct_id>NCT01212263</nct_id>
  </id_info>
  <brief_title>Clomiphene Citrate (CC) Co-treatment With HP Urinary FSH vs HP Urinary FSH in CC-resistant PCOS</brief_title>
  <official_title>Clomiphene Citrate Co-treatment With Low Dose HP Urinary FSH vs. HP Urinary FSH Step-up Protocol for Clomiphene-citrate Resistant PCOS Anovulatory Infertility: Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura Integrated Fertility Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura Integrated Fertility Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To test whether adding small doses of HP urinary FSH to standard regimen of clomiphene
      citrate in clomiphene resistant PCOS well yield better results in terms of better ovulation
      rate,lower follicle number, less consumption of HP urinary FSH,lower treatment cost , better
      pregnancy rate, lower multiple pregnancy rates compared with the exclusive use of HP urinary
      FSH in these cases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To test whether CC co- treatment with chronic low dose HP uFSH vs chronic low dose HP uFSH in
      CC resistant PCOS will yield better results in terms of ,ovulation rate, lower follicle
      number,lower HP uFSH dose ,better outcome in terms of pregnancy rates, better
      cost-effectiveness ratio, lower multiple pregnancy rates,lower cycle cancellation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ovulation rate</measure>
    <time_frame>6 months</time_frame>
    <description>IF CC Co-treatment with low dose step-up HP urinary(u)FSH results in similar or higher ovulation rate compared with step-up low dose HP uFSH</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Live birth rate</measure>
    <time_frame>6 months</time_frame>
    <description>% of of cases that result in live birth &gt; 20 weeks pregnancy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of follicles sized 16 mm or more mean diameter in both ovaries at the time of hCG</measure>
    <time_frame>3 months</time_frame>
    <description>To test if CC-co treatment with low dose HP uFSH results in lower number of follicles 16 mm mean diameter or more at time of triggerring ovulation compared with low dose HP uFSH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endometrial thickness</measure>
    <time_frame>3 months</time_frame>
    <description>Measuring endometrial thickness in mm in both study arms at the time of ovulation trigerring to see if there is difference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum Estradiol(E2)</measure>
    <time_frame>3 months</time_frame>
    <description>serum level of E2 is measured in both groups at the time of ovulation triggerring to test for differences</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of multiple pregnancy</measure>
    <time_frame>3 months</time_frame>
    <description>To test if CC-co treatment with low dose HP uFSH results in lower or higher incidence of multiple pregnancies compared with low dose HP uFSH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>costs per cycle</measure>
    <time_frame>3 months</time_frame>
    <description>costs of drugs used to induce ovulation in each arm of the study in Egyptian pounds The cost of HP uFSH per cycle was calculated by multiplying the cost of a single IU with the mean number of FSH IU used per cycle. Add to this the cost of clomiphene citrate in the relevant arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cost effectiveness ratio</measure>
    <time_frame>6 months</time_frame>
    <description>The cost-effectiveness ratio is calculated multiplying the cost per cycle by the total number of cycles performed in each arm then dividing the result for the number of clinical pregnancies obtained in the arm during the trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical and biochemical predictors of response to treatment</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">174</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Clomiphene Citrate plus HP uFSH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Starting from the 2nd day of the cycle Clomiphene Citrate( CC)50 mg tablets are given in 100 mg daily dose for 5 days together with an low dose HP uFSH (half ampoule: 37.5 IU) given im daily for 8-10 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Step-up HP uFSH</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HP uFSH started in doses of half ampole (37.5 )IU daily from the 2nd day of cycle for 7 days ,then dose is stepped-up to one ampoule ( 75 IU) for 7 days then the one and a half amps (112.5) IU /day until follicular diameter reaches 18 mm mean diameter</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Step-up HP u FSH</intervention_name>
    <description>HP u FSH (Fostimone 75 IU ,IBSA Institut Biochimique SA-CH 6903 Lugano) in doses of 37.5 IU (half ampole) im /day statrted from second day of the cycle for 7 days ,then increased to 75 IU for another 7 days ,then to 112.5 IU (one and half ampoule) untilleading follicle mean diameter reaches 18 mm</description>
    <arm_group_label>Step-up HP uFSH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clomiphine citrate plus low dose uFSH</intervention_name>
    <description>Clomiphene citrate 50 mg tab oral tablets(Clomid 50 mg tablets Global Napi , Egypt) two tablets(100 mg) /day are started from the 2nd day of cycle for 5 days togeteher with 37.5 IU HP uFSH (Fostimone 75 IU IBSA)/day for 8 days and may be extended to 10-12 days until leading follicle diameter reaches 18 mm</description>
    <arm_group_label>Clomiphene Citrate plus HP uFSH</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CC resistant PCOS

          -  Infertile

          -  Females

          -  Age 18-38

        Exclusion Criteria:

          -  Hyperprolactinaemia

          -  Cushing syndrome

          -  Adult onset adrenal hyperplasia

          -  Age &gt;38

          -  Other infertility factors in the couple than PCOS: male factor,tubal
             factor,edometriosis
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamad E Ghanem, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mansoura Integrated Fertility Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohammad A Emam, MD</last_name>
    <role>Study Director</role>
    <affiliation>Mansoura Integrated Fertility Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamad E Ghanem, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mansoura Integrated Fertility Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mansoura Integrated fertility Center</name>
      <address>
        <city>Mansoura</city>
        <state>Dekahlia</state>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Palomba S, Falbo A, Zullo F. Management strategies for ovulation induction in women with polycystic ovary syndrome and known clomifene citrate resistance. Curr Opin Obstet Gynecol. 2009 Dec;21(6):465-73. doi: 10.1097/GCO.0b013e328332d188. Review.</citation>
    <PMID>19809318</PMID>
  </reference>
  <reference>
    <citation>Gorry A, White DM, Franks S. Infertility in polycystic ovary syndrome: focus on low-dose gonadotropin treatment. Endocrine. 2006 Aug;30(1):27-33. Review.</citation>
    <PMID>17185789</PMID>
  </reference>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2010</study_first_submitted>
  <study_first_submitted_qc>September 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2010</study_first_posted>
  <last_update_submitted>May 29, 2013</last_update_submitted>
  <last_update_submitted_qc>May 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura Integrated Fertility Center</investigator_affiliation>
    <investigator_full_name>Mohamad Elsaid Ghanem</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>PCOS</keyword>
  <keyword>Clomiphene resistance</keyword>
  <keyword>ovulation induction</keyword>
  <keyword>low dose uFSH</keyword>
  <keyword>uFSH step-up protocol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Clomiphene</mesh_term>
    <mesh_term>Enclomiphene</mesh_term>
    <mesh_term>Zuclomiphene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

